Last reviewed · How we verify
Trastuzumab or Lapatinib — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Trastuzumab or Lapatinib (Trastuzumab or Lapatinib) — Azienda Ospedaliera Ordine Mauriziano di Torino.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Trastuzumab or Lapatinib TARGET | Trastuzumab or Lapatinib | Azienda Ospedaliera Ordine Mauriziano di Torino | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Trastuzumab or Lapatinib CI watch — RSS
- Trastuzumab or Lapatinib CI watch — Atom
- Trastuzumab or Lapatinib CI watch — JSON
- Trastuzumab or Lapatinib alone — RSS
Cite this brief
Drug Landscape (2026). Trastuzumab or Lapatinib — Competitive Intelligence Brief. https://druglandscape.com/ci/trastuzumab-or-lapatinib. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab